STING inhibitors target the cyclic dinucleotide binding pocket

Ze Hong(China Pharmaceutical University), Jiahao Mei(China Pharmaceutical University), Chenhui Li(China Pharmaceutical University), Guohui Bai(Shanghai Jiao Tong University), Munire Maimaiti(China Pharmaceutical University), Hai Hu(China Pharmaceutical University), Wenying Yu(China Pharmaceutical University), Li Sun(China Pharmaceutical University), Lele Zhang(Chinese Academy of Sciences), Dan Cheng(China Pharmaceutical University), Yixian Liao(China Pharmaceutical University), Senlin Li(Chinese Academy of Sciences), Yanping You(China Pharmaceutical University), Hongbin Sun(China Pharmaceutical University), Jing Huang(Shanghai Jiao Tong University), Xing Liu(Chinese Academy of Sciences), Judy Lieberman(Boston Children's Hospital), Chen Wang(China Pharmaceutical University)
Proceedings of the National Academy of Sciences
June 7, 2021
Cited by 239Open Access
Full Text

Abstract

Significance cGAS (cytosolic DNA sensor cyclic AMP-GMP synthase)-STING (stimulator of interferon genes) signaling is critical for sensing cytosolic DNA to initiate host immune responses against invading pathogens and cancer. However, inappropriate activation of STING signaling causes severe and often fatal autoimmune or autoinflammatory diseases. Hence, STING is an attractive drug target for the treatment of STING-driven autoimmune and inflammatory disorders. Therefore, there is a need to identify lead compounds that effectively inhibit human STING for further drug development. Here, we identified and characterized a STING-specific inhibitor SN-011 with high efficiency, specificity, and safety, paving the way for therapeutically manipulating STING-mediated clinical diseases.


Related Papers

No related papers found

Powered by citation graph analysis